Won Second Place at the “PharmaEssentia Innovation Award 2026”

FerroptoCure Co., Ltd. won second place at the “PharmaEssentia Innovation Award 2026,” held in July 2026.

This award is an international pitch event targeting innovative startups in the drug discovery and biotechnology fields, with entries judged based on criteria such as technological novelty, impact on healthcare, and business viability.

Our company received this award in recognition of our unique drug discovery approach focused on ferroptosis and our presentation of new therapeutic possibilities.

FerroptoCure will further advance the research and development of innovative cancer treatments based on ferroptoCure, while strengthening collaborations with companies and research institutions both in Japan and abroad, with the goal of growing into a globally expanding drug discovery company. We will continue to advance drug discovery and development to deliver new treatment options to patients around the world.

関連記事：The PharmaEssentia Innovation Award 2026
関連ページ：CEOmessage